Follow
Stayble Therapeutics AB
Nasdaq First North Sweden (Sweden)
Stayble Therapeutics AB is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain b Stayble Therapeutics AB is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Read more

Sector:
HEALTH CARE
>
Biotechnology
Healthcare
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
STABL
SE0013513652
Nasdaq First North Sweden
Sweden (SE)
Details of share in Stayble Therapeutics AB with ticker STABL
Status
Active
Order book id
Amount of instruments
6 916 340
Par value
Market cap
Currency
SEK
Segment
First North
First trading date
09 Mar 2020
Terms
Type
Price
Pre-money valuation
Time
Files
IPO
12.30 SEK
50.02M SEK
04 Feb - 18 Feb 2020
IPO in Stayble Therapeutics AB
Type
Ticker
ISIN
Market
OPTION
STABL TO1
SE0013748381
Nasdaq First North Sweden
Sweden (SE)
Details of option in Stayble Therapeutics AB with ticker STABL TO1
Status
Active
Order book id
Amount of instruments
2 850 000
Market cap
Currency
SEK
Segment
First North
Trading period
09 Mar 2020 - 24 Nov 2020
Terms
One (1) subscription option of the TO1 series, entitles the holder to subscribe for a one (1) new share.
The subscription price for subscription of shares based on subscription options amounts to the volume-weighted price of The Company's share during the period from 30 October to 13 November 2020 at a discount of 30 per cent, but not less than SEK 12.30 and a maximum of SEK 24.60.
Type
Price
Pre-money valuation
Time
Files
Exercise
12.30-24.60 SEK
17 Nov - 01 Dec 2020
Option exercise terms for STABL TO1
People
Number of Employees
2 people
Andreas Gerward
CEO
Catharina Bäärnhielm Marklund
Chairman of the board
Kjell Olmarker
Board member
Patrik Sjöstrand
Board member
Jane Laursen
Board member
Pontus Ottosson
Board member
Company Details
Sector
HEALTH CARE

Address
Medicinaregatan 8 A
Zip code
413 90
City/district
Gothenburg
Country
Sweden (SE)
Registration number
5590248372
LEI code
549300WD23DE1US21868
First trade date
09 Mar 2020
Registration date
01 Sep 2015
Short name
Stayble Therapeutics

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date